Accelerated Bio and Pluristyx Generate Clinical-Grade Induced Pluripotent Stem Cells from Reprogrammed Human Trophoblast Stem Cells

Accelerated Biosciences, in collaboration with Pluristyx, has successfully developed clinical-grade induced pluripotent stem cell (iPSC) lines using a newly developed starting material. This milestone achievement involves Accelerated Bio’s ethically sourced preimplantation human trophoblast stem cells (hTSCs), known for their unique plasticity and robust low-passage expansion capabilities. These “young” cells represent a significant advancement in stem cell research, promising new avenues for medical applications.

Pluristyx’s Proprietary mRNA Reprogramming Technology and Accelerated Bio’s hTSC Platform to Transform the Industry

Pluristyx reprogrammed two separate donor stocks of Good Manufacturing Practice (GMP) accredited hTSCs using their proprietary mRNA reprogramming technology. Starting with hTSCs, they generated multiple iPSC clones. These clones will serve as seed stock for GMP master cell banks. This approach marks a significant advancement in stem cell technology. Currently, researchers can access research-use-only counterparts of the clinical grade hTSC-derived iPSC lines for testing purposes.

Benjamin Fryer, CEO of Pluristyx, shared his excitement about the collaboration, stating, “Our partnership with Accelerated Bio aligns perfectly with our mission to make iPSCs more accessible to the industry. By leveraging our advanced reprogramming technology, we aim to diversify the iPSC market, offering more choices for cell therapy development.”

Yuta Lee, CEO of Accelerated Bio, highlighted the innovative features of the hTSC platform, saying, “Our hTSC platform is not only the earliest ethically sourced pluripotent stem cell source but also one of the most dynamic and versatile. This collaboration with Pluristyx underscores the transformative potential of hTSCs in the cell therapy industry.”

Collaboration Innovating Precision Medicine and Therapeutic Solutions Through Stem Cell Technologies

The therapeutic development industry shows great enthusiasm for iPSCs due to their potential to address gaps in cell therapy and medicine. Currently, few organizations provide complete solutions from GMP cell line acquisition through to clinical and commercial manufacturing at scale for iPSCs. Key challenges include improving reprogramming efficiency, ensuring genomic integrity and stability, scaling up manufacturing, and implementing iPSCs clinically. These technical hurdles need to be overcome to unlock their full potential.

Accelerated Bio focuses on healthcare innovation through hTSCs, aiming to revolutionize precision medicine. These stem cells are among the first ethically sourced pluripotent stem cell sources available. Obtained early in development, these stem cells are known for their genetic stability, natural immune privilege, and capacity for extensive expansion. The company’s intellectual property portfolio supports ongoing innovation. Further, Pluristyx offers a variety of iPSC-based technologies and genetic engineering tools through its panCELLa Platform, providing comprehensive client support from research to clinical application. Known for its expertise in gene-edited iPSC and cell therapy solutions, Pluristyx facilitates efficient pathways to commercialization for cell-based therapeutics. This collaboration is presented as a significant endorsement of the potential for hTSCs to bring transformative advancements to the field of cell therapy.

Author

Bernice Lottering